ADC Therapeutics S.A.
ADC Therapeutics S.A. (ADCT) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · ADCT · as of Sep 30, 2025
Ownership Breakdown
108
Institutional Holders
▲ 17 vs Q2
$271.32M
Total Inst. Value
▲ $88.25M vs Q2
127.19M
Shares Outstanding
freeFloat 76.93%
67.83M
13F Shares Held
▼ 478,239 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
ADCT largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
REDMILE GROUP, LLC pharmaceutical preparations | 15.67M | 13.77% | 13.77% | $62.67B | Nov 14, 2025 | — held |
POINT72 ASSET MANAGEMENT, L.P. pharmaceutical preparations | 8.14M | 7.15% | 7.15% | $32.54B | Nov 14, 2025 | ▲ 372.0K |
PROSIGHT MANAGEMENT, LP pharmaceutical preparations | 7.47M | 6.57% | 6.57% | $29.89B | Nov 14, 2025 | ▼ 3.00M |
ORBIMED ADVISORS LLC pharmaceutical preparations | 5.91M | 5.19% | 5.19% | $23.63B | Nov 14, 2025 | — held |
BLACKROCK, INC. pharmaceutical preparations | 4.51M | 3.97% | 3.97% | $18.05B | Nov 12, 2025 | ▼ 9.6K |
MORGAN STANLEY pharmaceutical preparations | 3.67M | 3.23% | 3.23% | $14.68B | May 27, 2026 | ▲ 623.5K |
NANTAHALA CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 2.27M | 1.99% | 1.99% | $9.07B | Nov 14, 2025 | — held |
GOLDMAN SACHS GROUP INC pharmaceutical preparations | 1.59M | 1.40% | 1.40% | $6.38B | Nov 14, 2025 | ▲ 51.8K |
TCG CROSSOVER MANAGEMENT, LLC pharmaceutical preparations | 1.39M | 1.22% | 1.22% | $5.56B | Nov 17, 2025 | NEW |
BANK OF AMERICA CORP /DE/ pharmaceutical preparations | 1.36M | 1.20% | 1.20% | $5.45B | Feb 3, 2026 | ▼ 837.8K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
20
Increased
+3.24M shares10
New Positions
first time holders9
Decreased
−7.17M shares0
Sold Out
fully exitedNet shares change (top 50)
3.93M
+3.24M / −7.17M
Net new holders
+21
10 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
ADCT insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
0
Buy transactions
4
Sell transactions
0.00
Buy/Sell ratio
$5M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Redmile Group, LLC 10 percent owner | Mar 31, 2026 | Sale | 196,229 | $3.75 | $736.3K | 15.47M | Form 4 ↗ |
Redmile Group, LLC 10 percent owner | Apr 1, 2026 | Sale | 169,265 | $3.80 | $643.0K | 15.30M | Form 4 ↗ |
Redmile Group, LLC 10 percent owner | Mar 31, 2026 | Sale | 188,407 | $3.75 | $706.9K | 12.96M | Form 4 ↗ |
Redmile Group, LLC 10 percent owner | Apr 1, 2026 | Sale | 162,517 | $3.80 | $617.4K | 12.79M | Form 4 ↗ |
Redmile Group, LLC 10 percent owner | Apr 2, 2026 | Sale | 2,634,506 | $3.28 | $8.64M | 12.67M | Form 4 ↗ |
Redmile Group, LLC 10 percent owner | Apr 2, 2026 | Sale | 2,529,491 | $3.28 | $8.29M | 10.27M | Form 4 ↗ |
Kallebo Lisa Michelle Chief Accounting Officer | Feb 13, 2026 | Award | 62,900 | $3.99 | $251.0K | 133.7K | Form 4 ↗ |
Kallebo Lisa Michelle Chief Accounting Officer | Feb 13, 2026 | Tax Withhold | 5,433 | $3.99 | $21.7K | 128.2K | Form 4 ↗ |
Zaki Mohamed Chief Medical Officer | Feb 13, 2026 | Award | 285,200 | $3.99 | $1.14M | 707.0K | Form 4 ↗ |
Zaki Mohamed Chief Medical Officer | Feb 13, 2026 | Tax Withhold | 24,603 | $3.99 | $98.2K | 682.4K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
ADC Therapeutics S.A. (ADCT) is primarily owned by institutional investors, who hold approximately 53.3% of total shares outstanding. Company insiders own approximately 23.07%, while retail and public investors account for the remaining 23.60%.
The largest institutional shareholder of ADC Therapeutics S.A. is REDMILE GROUP, LLC, holding approximately 15.67 million shares — equal to 13.77% of outstanding shares — as of September 30, 2025.
A total of 108 institutional investors currently hold ADCT stock, with a combined institutional value of approximately $271,318,744 as of the most recent 13F filing period.
Frequently asked questions
ADCT ownershipADC Therapeutics S.A. (ADCT) is primarily owned by institutional investors, who hold approximately 53.3% of shares. The largest shareholder is REDMILE GROUP, LLC with a 13.77% stake. Company insiders hold 23.07%. Data sourced from SEC Form 13F as of September 30, 2025.